A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Gemcitabine
- Indications Leiomyosarcoma; Uterine cancer
- Focus Therapeutic Use
- 14 Feb 2014 Biomarkers information updated
- 13 Feb 2009 Primary outcome amended as reported by ClinicalTrials.gov.
- 13 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.